-
SEOM-GEMCAD-TTD Clinical Guidelines for the Adjuvant Treatment of Colon Cancer (2023)
The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.
-
ESMO China Highlights | Dr. Yanhong Deng: Bispecific Antibody Ivonescimab Offers a New Option for Personalized Treatment of MSS mCRC
Oncology Frontier: Could you briefly introduce the current first-line treatment landscape for mCRC and the background of your study design? Dr. Yanhong Deng: The first-line treatment strategy for mCRC is…
-
Dr. Yong Zeng: Sharing the Experience of Perioperative ERAS Application in Liver Resection at West China Hospital
1. What Can ERAS Bring to Surgical Care? A meta-analysis published in Clinical Nutrition explored the differences in outcomes between patients undergoing major elective open colorectal surgery under the ERAS…
-
Breaking News: Dr. Jianwei Zhang Reports Top 10 Advances in Colorectal Cancer Research in 2023
Background of Research Selection and Recommendations Under the guidance of the Chinese Society of Clinical Oncology (CSCO), Peking University Library retrieved 6,435 publications on colorectal cancer from the SCI database.…
-
Dr. Yongsheng Li’s Team Reviews the Mechanisms and Clinical Studies of ADCs in Cancer Therapy
Recently, Dr. Yongsheng Li’s team from Chongqing University Cancer Hospital published a comprehensive review titled “Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies” in the high-impact journal MedComm (IF:…
-
Enhancing Clinical Trials with Real-World Data: Insights from the MORPHEUS PDAC Study
The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).
-
Optimizing MGMT Gene Promoter Hypermethylation Detection: Insights from a Comparative Study
A recent publication in Diagnostics delves into the critical comparison between two cutting-edge molecular techniques—Methyl-BEAMing and Droplet Digital PCR (ddPCR)—for detecting MGMT gene promoter hypermethylation. This biomarker plays a pivotal role in various cancers, particularly glioblastomas, as it helps predict patient response to alkylating agent-based chemotherapy.
-
Evolution of Dosimetric Parameters Through PRRT: Insights from the Phase II LUMEN Study
The phase II LUMEN study explores the dynamic changes in dosimetric parameters during Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTA-TATE for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study reveals significant variability in absorbed doses and activity concentrations, particularly when comparing tumor sites to organs-at-risk such as the kidneys and red marrow. In pancreatic NETs,…
Connecting Medical Expertise through Media